Skip to main content

Exact Sciences to Participate in November Investor Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

  • Jefferies London Healthcare Conference, London

    Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30 p.m. GMT)

The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences (Nasdaq: EXAS) helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like the Cancerguard® test for multi-cancer early detection and the Oncodetect® test for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow @ExactSciences on X, or connect on LinkedIn and Facebook.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  260.20
-2.84 (-1.08%)
AAPL  272.38
+2.21 (0.82%)
AMD  351.75
+14.64 (4.34%)
BAC  53.38
+0.49 (0.94%)
GOOG  379.63
+32.32 (9.31%)
META  609.71
-59.41 (-8.88%)
MSFT  400.04
-24.42 (-5.75%)
NVDA  200.15
-9.10 (-4.35%)
ORCL  161.19
-2.64 (-1.61%)
TSLA  378.45
+5.65 (1.52%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.